* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Local Anesthetics
Survey
Document related concepts
Transcript
1 LA: Reversibly block impulse conduction along nerve axons & other excitable membrane that utilize Na+ channels for Action Potential generation. Uses: block pain sensation (nociception) from specific area of ! body. Cocaine was ! 1st LA isolated from Coca plant as an ophthalmic anesthetic; Its chronic use: psychological dependence (addiction). 2 Followed by procaine & then Lidocaine (Lid) which is ! most widely used LA. What characteristics of LAs make them ideal agents for anesthesia? As ropivacaine 1- Rapid onset, 2- Long Duration of Action, 3- Reversible & selective blockade of sensory nerves without motor blockade, 4- Minimal local tissue irritation & no systemic toxicities. 3 Chemistry of LA Weak base & available as salts to increase solubility & stability. Consist of lipophilic gp (aromatic ring): memb penetration ++ intermediate chain via an ester or amide to ionizable gp: for channel blockade . 4 5 6 7 • Absorption esp systemic: depends on: 1- dosage, 2- site of inj, (VASCULARITY): IV > tracheal > intercostals > paracervical > epidural > brachial plexus > sciatic > SC 3- drug-tissue binding, 4- local bld flow, 5- use of Vasoconstrictors (epinephrine/ phenylephrine) & 6- ! physiochemical property of ! drug. Absorption in highly vascular area is > poor perfused tissue. 8 Epinephrine/ VC: Slow ! removal & reduce systemic absorption of LA from inj site by decreasing bld flow & cause higher local tissue conc of ! drug & prolong conduction blockade. + reduce CNS & systemic tox. Used with short/ intermediate duration of action: (procaine, Lid & mepivacaine). VCs are < effective in prolonging anesthetic action of more lipid-soluble, long-acting drugs (bupivacaine & ropivacaine) which are highly tissue-bound. 9 Distribution ! Amide LAs are widely distributed after IV bolus inj. Initial rapid phase into highly perfused organs, then a slower phase to moderately perfused organs. 10 Metabolism & Excretion Acidification of urine: ionization & excretion of LA Ester-type hydrolyzed rapidly in ! bld (by pseudo-choline-sterase) to inactive metabolite; short plasma t1/2 (< 1 min). ! amide linkage is hydrolyzed by liver cyto P450 with diff rate (prilocaine (fastest) > Lid > mepivacaine > ropivacaine > bupivacaine (slowest). All converted to water-soluble metabolites & excreted in urine. 11 Toxicity from amide-type LA occur in hepatic D. Ex: elimination t1/2 of Lid from 1.6 hr in normal pat to > 6 hr in liver disease pat. amide LA also affected by enz inhibitors. Reduced hepatic bld flow: decrease their elimination. 12 MOA Block ! Initiation & propagation of AP by preventing voltage-gated Na+ channels. Activity is PH-dependent, increased at alkaline PH. Its penetration to Na+ chs is very poor at acid PH. Inflamed tissues (acidic): resis to LA. Elevated extracellular Ca2+ antagonizes ! action of LA by Ca2+ w increase! surface potential on ! membrane. 13 Structure- Activity Characteristics of LA: Smaller & more lipophilic LA: ! Faster rate of interaction with Na+ chs. Potency is +vely correlated with lipid solubility. Lid, procaine, & mepivacaine are > water-soluble than tetracaine, bupivacaine, & ropivacaine that are more potent & have longer DOA. Long acting (bupivacaine ) also bind more extensively to plasma proteins & can be displaced by other drugs. 14 Other actions on nerves: 1- Loss of sensation from site of painful stimuli 2- Motor paralysis during surgery Disadvantages In Spinal anesthesia, motor paralysis: impair respiratory activity & AN blockade: hypotension & urinary retention (catheterization). 15 1- Effect on fiber diameter: LA block conduction in small-diameter nerve fibers > readily than in large fibers. Pain sensation is blocked > readily than other sensory modalities. Motor axons (large diameter), are relatively resistance. LAs block conduction in ! following order: small myelinated (nociceptive impulses), non- myelinated (C-fibers), large myelinated axons. 16 2- Effect on firing frequency Blockade by LA is > at higher frequencies of depolarization. Sensory (esp pain) fibers have High firing rate & long AP duration. while Motor fibers fire at a slower rate & have shorter AP duration. 17 Properties of LAs Drug Onset Dura Plas tion ma t1/2 Coc- M M Pro- M Short 1 hr SE Notes CV & CNS Rarely used, only as spray for URT < CNS: No longer 1hr restlessness used , shivering, anxiety CVS: B.cardia & decrease COP 18 Lid Rapid M As procaine but < tendency to CNS As Lid Widely used + IV in ventricular arrhythmia. Mepivacaine is similar spinal & corneal anesthesia. Bupivac Slow Long 2 hr - As Lid but > CVS Priloc- No VD MetHgemi a Widely used (long DOA). Ropivacine is similar, with less cardioTox. Widely used, not for obstetric (neonatal 19 metHgemia. Long Ametho V. cSlow (tetrac M M 2 hr 1 hr 2 hr Classification: Six Placement Sites Surface/topical anesthesia Local infiltration Peripheral nerve block Bier block (IV regional anesthesia) Epidural anesthesia Spinal anesthesia (subarachnoid) 20 Epidural Spinal 21 22 Clinical pharm Effective analgesia in specific regions of ! body. Route of administration: 1- Topical/ surface application (nasal mucosa, wound margins) 2-Inj in ! vicinity of peripheral nerve endings (infiltration) & major nerve trunks (blocks) 3- Inj into ! epidural or subarachnoid spaces surrounding ! spinal cord. 4- IV regional anesthesia (Bier block) for surgery < 60 min in limbs. 23 Local Infiltration: Extravascular placement of ! LA in ! region to be anesthetized Peripheral Nerve Block: LA inj into tissues around individual nerves or nerve plexuses (e.g. brachial plexus). 24 DOA Short: proc- & chloropro- caine Intermediate: Lid, mepiva- & prilo- caine Long-acting: tetra-, bupiva-, & ropivacaine. DOA can be prolonged by increasing ! Dose/ adding VC agent. 25 To increase onset of LA: + Na-bicarbonate to LA sol. Repeated inj of LA: tachyphylaxis (extracellular acidosis) Pregnancy increase LA tox. Topical LA: eye, ENT & for cosmetic surgery. Properties: 1- rapid penetration across ! skin/ mucosa & 2- low tendency to diffuse away from ! site of application. Cocaine bec of excellent penetration & local VC used for (ENT) procedures. Has irritating effect so NOT used in ophthalmic procedure. Other topical: Lid + VC, tetracaine, pramoxine, dibucaine, benzocaine, & dyclonine. 26 OTHER USES: LAs have membrane-stabilizing effects; Both IV Lid & po (mexiletine, tocainide) used to Tr pat with neuropathic pain syndrome: (uncontrolled, rapid, sensory fiber firing). Systemic LA: as adjuncts to TCA (amitriptyline) & anticonvulsant (carbamazepine) combination. Systemic toxicity: CNS & CV system. 27 Toxicity A- CNS: 1- All LAs at low conc: sleepiness, light headiness, visual & auditory disturbances & restlessness. Early symp: tongue numbness + metallic taste. Rare, but High plasma conc.: nystagmus & muscular twitching, then tonic-clonic convulsions. Followed by generalized CNS depression (apnea). 28 Convulsions: excessive LA level in ! bld. If large dose of LA is required: Rx pre-medication with BDZs prophylaxis. 2- For cocaine: widely abuse drug, severe CV toxicity; HTN, arrhythmia, & myocardial Failure. B- Neurotox: direct neuronal tox. With excessive high conc. Chloroprocaine & Lid are > neurotoxic than others in spinal anes.,: transient irritation (neuropathic symptoms). 29 C- CVS: direct effect on ! hrt & smooth muscle & indirect effect on ! ANS. Depress strength of cardiac contraction, ECG changes & cause arteriolar dilatation;; hypotension. Cocaine blocks Norepinephrine uptake: VC & HTN + cardiac arrhythmia & ischemia. Bupivacaine is > cardiotoxic than other long-acting LA. Ropivaciane: CV & CNS tox, but < than Bupivacaine. 30 D- Hematologic effects: Large dose of prilocaine: accumulation of Oxidizing Agent (o- toluidine) that convert Hg to metHg.;; cyanosis & chocolate-colored. Not recommended in infants. (Benzocaine can also cause metHg). Rx: IV methylene blue/ ascorbic acid. E- Allergic rxs: (Not e amides) Ester-type LAs are metabolized to P-ABA derivatives; allergic rxs. 31